Mr. Stephen Van Deventer reports

PREVECEUTICAL CLOSES INITIAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

Further to the news release dated Aug. 5, 2025, Preveceutical Medical Inc. has closed an initial tranche of its previously announced $1-million non-brokered private placement, which initial tranche consisted of the issuance of 16,162,500 units of the company at a price of four cents per unit for gross aggregate proceeds of $646,500.

Each unit is composed of one common share in the capital of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of six cents per warrant share for a period of 24 months from the closing of the initial tranche, subject to an acceleration right, whereby the expiry date of the warrants may be accelerated if the daily closing price of the shares equals or exceeds 18 cents or greater on the Canadian Securities Exchange (or such other recognized securities exchange on which the shares may then trade) for a minimum of 10 consecutive trading days, in which event the company may accelerate the expiry of the warrants by giving notice by news release, and, in such case, all of the then unexercised warrants will expire on the 30th day after the date on which the news release is disseminated.

In connection with the initial tranche closing, the company paid finders' fees to three eligible finders composed of $23,600 in cash and issued 590,000 finders' warrants. The finder's warrant is exercisable into one additional share at an exercise price of six cents per share for 24 months from the initial tranche closing, subject to the acceleration right.

The company intends to use the aggregate gross proceeds of the initial tranche to pay outstanding payables, for operating expenses and for general working capital purposes.

Preveceutical intends to close a second tranche for the rest of the offering in the coming weeks.

All securities issued in relation to the initial tranche are subject to a hold period expiring four months and one day after the initial tranche closing in accordance with applicable securities laws.

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.